Residual viremia (RV) is present in most if not all patients who are responding well to highly activeantiretroviral therapy (HAART). It now appears that HAART reduces viremia to new steady state level thataverages around 1 copy of HIV-1 RNA/ml of plasma. This steady state appears to persist indefinitely with nofurther decay. Because the half life of virions in the plasma is short (minutes to hours), the continuedpresence of free virus in the plasma of patients on HAART indicates ongoing virus production. Thus it isclear that the sources of RV must be understood if HIV-1 eradication is to be achieved. In the previousfunding period, we have carried out the first study of intensification of a standard HAART regimen. Wefound that intensification fails to reduce RV, indicating that most of the RV results from release of virus fromstable reservoirs of cells infected prior to the initiation of therapy. These results indicate that the theoreticalpotential of HAART to control viremia has already been reached and that further progress towards HIVeradication will require new strategies that directly target stable reservoirs. Through the clonal analysis ofRV, we have also found that the RV there is at least one other source of RV in addition to the stablereservoir in resting CD4+ T cells. We now propose to continue studies of RV to obtain clones of replication-competent virus from the RV. This will provide direct evidence that the viruses constituting the RV are ofpotential clinical significance. In addition, in a new project prompted by the interest in our intensificationstudy, we will study patients who have stable low level viremia in the range of 75-400 copies/ml. Thesepatients currently represent a significant clinical dilemma. The presence of detectable viremia often triggersa change in regimen. However, it is possible that stable low level viremia reflects release of virus from stablereservoirs that are larger in some patients than in others. Thus we will carry out a detailed analysis of lowlevel viremia in these patients in order to provide a molecular explanation for persistent low level viremia andto obtain additional insight into stable viral reservoirs.

Public Health Relevance

;Most pafients who are doing well on combination therapy for HIV infection have trace levels of free virus inthe blood called residual viremia. We have shown that this residual viremia is due to the release of virusfrom stable reservoirs of infected cells that persist despite the presence of antiretroviral drugs. Progresstowards HIV eradication will require the identification and elimination of these reservoirs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37AI051178-11
Application #
8188707
Study Section
Special Emphasis Panel (NSS)
Program Officer
Salzwedel, Karl D
Project Start
2002-01-01
Project End
2017-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
11
Fiscal Year
2012
Total Cost
$243,000
Indirect Cost
$93,000
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Eriksson, Susanne; Graf, Erin H; Dahl, Viktor et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9:e1003174
Ho, Ya-Chi; Shan, Liang; Hosmane, Nina N et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-51
Durand, Christine M; Blankson, Joel N; Siliciano, Robert F (2012) Developing strategies for HIV-1 eradication. Trends Immunol 33:554-62
Eisele, Evelyn; Siliciano, Robert F (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377-88
Spivak, Adam M; Rabi, S Alireza; McMahon, Moira A et al. (2011) Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses 27:759-61
Siliciano, Janet D; Siliciano, Robert F (2010) Biomarkers of HIV replication. Curr Opin HIV AIDS 5:491-7
McMahon, Moira A; Siliciano, Janet D; Kohli, Rahul M et al. (2010) Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 24:319-23
Chase, Amanda J; Yang, Hung-Chih; Zhang, Hao et al. (2008) Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 82:8307-15
Sedaghat, Ahmad R; German, Jennifer; Teslovich, Tanya M et al. (2008) Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 82:1870-83
Sedaghat, Ahmad R; Siliciano, Robert F; Wilke, Claus O (2008) Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis 8:2

Showing the most recent 10 out of 15 publications